Skip to main content
Premium Trial:

Request an Annual Quote

CORRECTED: German Group Explores SARS Coronavirus Proteinase Structure

This article has been corrected from a previous version, which contained scientific errors.

 

NEW YORK, May 13 - A group of German scientists has predicted the structure of a proteinases that controls replication in the SARS coronavirus based on homology modeling to existing coronavirus proteinases and has determined that drugs binding to active sites in these proteinases are likely to act on similar binding site in the SARS coronavirus proteinases, according to an article published online in Science today.

 

The group includes researchers from the University of L beck Institute of Biochemistry, the University of W rzburg Institute of Virology and Immunology, and the University of Jena Institute of Molecular Biology.

 

In the paper, they report on this viral proteinase, M(pro) or 3CL(pro), as an "active target for therapy." The researchers crystallized the structure of a similar proteinase M(pro) in human coronavirus 229-E, as well as that of an inhibitor complex of porcine coronavirus M(pro). Based on these structures, they constructed a homology model for M(pro) in the SARS coronavirus. This work led them to conclude that the substrate-binding sites in the SARS coronavirus are similar to those in these better-characterized coronaviruses, and that existing agents designed to work on the binding sites of other coronavirues are likely, with modification, to work on the SARS coronavirus M(pro) proteinase binding site.

 

This latest work comes just after an analysis of different SARS coronavirus' sequences was published in the Lancet. Scientists have remarked as to the rapid progress of genomic-based research on this syndrome.

 

GenomeWeb Coverage of SARS

 

Genome Institute of Singapore Collaborates with Hemispherix on RNA-based SARS Therapeutic (May 13, 2003)

Study Analyzes How SARS Virus Changed As It Spread Across the Globe (May 9, 2003)

InforSense Donates KDE Software to Shanghai for SARS Research (May 8, 2003)

CombiMatrix Develops siRNA to Target SARS Virus (May 7, 2003)

///issues/news//121956-1.html"

Focus Tech Claims First RT-PCR SARS Diagnostic (May 5, 2003)

///issues/news//121956-1.html"May 2, 2003)

Roche to Launch RT-PCR-based SARS Diagnostic by July (April 28, 2003)

///issues/news//121956-1.html" Line...(April 25, 2003)

NCID said to Launch PCR Test for SARS Next Week ( ///issues/news//121956-1.html""Arial, Helvetica">CombiMatrix's Ali Arjomand on Developing a SARS Microarray (BioArray News, April 25, 2003)

///issues/news//121956-1.html".proteomonitor.com/articles/view-article.asp?Article=2003418112827">University of Manitoba Proteomics Researchers Tackle SARS Virus Proteins (ProteoMonitor, April 21, 2003)
///issues/news//121956-1.html"ial, Helvetica"> (April 17, 2003)

Singapore Genome Institute Joins SARS Sequencing Fray (April 16, 2003)

///issues/news//121956-1.html"ica">   (Apr 14, 2003)

CDC Completes SARS Virus Genome Draft On Heels of Canadian Team  (April 14, 2003)

///issues/news//121956-1.html"

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.